title: Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™).
abstract: Imatinib mesylate (Gleevec™, STI571), a selective inhibitor of BCR-ABL, c-Kit, and platelet-derived factor receptor, has been used to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors. Although its use has been associated with various adverse cutaneous reactions, pityriasis rosea-like drug eruptions are rare. Here, we report a case of pityriasis rosea-like drug eruption that developed following the administration of imatinib mesylate to treat CML.
authors.affiliation: Department of Dermatology, College of Medicine, Chungnam National University, Daejeon, Korea.
authors.forename: Ah Young
authors.initials: AY
authors.lastname: Cho
authors.forename: Dae Hun
authors.initials: DH
authors.lastname: Kim
authors.forename: Myung
authors.initials: M
authors.lastname: Im
authors.forename: Young
authors.initials: Y
authors.lastname: Lee
authors.forename: Young Joon
authors.initials: YJ
authors.lastname: Seo
authors.forename: Jeung Hoon
authors.initials: JH
authors.lastname: Lee